Clinical Oncology
Volume 19, Issue 2 , Pages 108-114, March 2007

Ifosfamide Encephalopathy

  • T. Ajithkumar

      Affiliations

    • Department of Oncology, Addenbrooke's Oncology Centre, Hills Road, Cambridge CB2 2QQ, UK
    • Corresponding Author InformationAuthor for correspondence: T. Ajithkumar, 51 Eland Way, Cambridge CB1 9XQ, UK. Tel: +44-1223-413306.
  • ,
  • C. Parkinson

      Affiliations

    • Department of Oncology, Addenbrooke's Oncology Centre, Hills Road, Cambridge CB2 2QQ, UK
  • ,
  • F. Shamshad

      Affiliations

    • Department of Oncology, Essex County Hospital, Lexden Road, Colchester CO3 3NB, UK
  • ,
  • P. Murray

      Affiliations

    • Department of Oncology, Essex County Hospital, Lexden Road, Colchester CO3 3NB, UK

Received 5 August 2005; received in revised form 10 October 2006; accepted 1 November 2006.

Abstract 

Encephalopathy is a potentially fatal toxicity of ifosfamide. Clinical manifestations of encephalopathy range from fatigue and confusion to coma and death. Early identification of this toxicity and prompt cessation of ifosfamide are the essential elements in the management of ifosfamide encephalopathy. Accurate prediction of this toxicity is often difficult. Based on the limited available evidence, methylene blue, an electron acceptor, may have a role in the treatment and the prevention of neurotoxicity. This paper reviews the current understanding of ifosfamide encephalopathy.

Key words: Encephalopathy, ifosfamide, methylene blue, nervous system, neurotoxicity

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0936-6555(06)00417-1

doi:10.1016/j.clon.2006.11.003

Clinical Oncology
Volume 19, Issue 2 , Pages 108-114, March 2007